Phase 1 Trial of KH801

• Status: NOT_YET_RECRUITING
• Trial end date: 2030-05-01

Summary

KH801 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Or 0.9% sodium chloride Injection.

This study is expected to include a total of approximately 17-42 participants.

• Phase: PHASE1

Details

• Lead Sponsor: Beijing Kanghong Biopharmaceutical Co., Ltd.